The Prostate Cancer Foundation of New Zealand is urging men to think carefully before relying on home PSA testing kits, warning that without proper medical guidance the results can be misleading and potentially dangerous.
As awareness of prostate cancer continues to grow, more men are looking for ways to assess their risk. Home PSA tests have become increasingly available, offering convenience, privacy and quick results. However, prostate cancer experts say the reality is far more complex than a single blood test.
Peter Dickens, Chief Executive of the Prostate Cancer Foundation of New Zealand, says while increased awareness is positive, men should not view home testing kits as a replacement for conversations with their doctor.
Understanding PSA Testing
PSA, or prostate-specific antigen, is a protein produced by the prostate gland. A PSA blood test measures the level of this protein in the bloodstream and is commonly used as a tool to assess a man’s risk of prostate cancer.
However, experts stress that PSA testing is not a simple yes-or-no test for cancer.
PSA levels can be influenced by age, family history, ethnicity, medications, prostate size, infections and other health conditions. This means results must be interpreted carefully within the broader context of an individual’s health.
A single PSA number does not provide a complete picture.
One of the Foundation’s biggest concerns is that men may misinterpret the results of home testing kits.
A normal PSA result does not necessarily mean a man is free from prostate cancer. Some men with clinically significant cancer may still have PSA levels that appear normal.
Conversely, an elevated PSA result does not automatically mean cancer is present.
Other conditions, including benign prostate enlargement and infections, can also cause PSA levels to rise.
Without medical guidance, men may either ignore serious symptoms because of a reassuring test result or become unnecessarily alarmed by results that may not indicate cancer at all.
Experts say both scenarios can have significant consequences for health outcomes and wellbeing.
The Foundation says discussing prostate health with a GP remains the most important step in making informed decisions about testing.
Doctors can assess individual risk factors, explain the benefits and limitations of PSA testing and determine whether further investigations are necessary.
A GP can also monitor changes in PSA levels over time, which is often more useful than relying on a single result.
Modern prostate cancer assessment increasingly takes into account a range of factors including age-adjusted risk, family history, genetic predisposition and follow-up investigations where required.
This personalised approach cannot be replicated by a stand-alone home testing kit.
The debate comes as concerns continue about the absence of a national prostate cancer screening programme in New Zealand.
Prostate cancer remains the most commonly diagnosed cancer in New Zealand men, with approximately 4,500 men diagnosed every year.
Around 740 New Zealand men die from the disease annually, making it one of the leading causes of cancer-related death among men.
The Prostate Cancer Foundation continues to advocate for a nationally coordinated, evidence-based screening programme that would provide consistent pathways for assessment and early detection.
The Foundation recommends that men discuss PSA testing with their doctor from age 50.
Men with close male relatives who have been diagnosed with prostate cancer should consider having that discussion from age 45.
Those with a strong family history of prostate, breast or ovarian cancer, or who carry the BRCA2 gene mutation, may need to start discussions from age 40.
Early detection remains one of the most effective tools available for improving treatment outcomes and reducing deaths from prostate cancer.
The Foundation’s message is straightforward: do not rely solely on a home test to make decisions about your health.
Instead, talk to a healthcare professional, understand your personal risk factors and ensure any testing forms part of a structured medical pathway.
For many men, prostate cancer develops without obvious symptoms in its early stages. That makes informed decision-making, regular discussions with healthcare providers and appropriate testing even more important.
As awareness of prostate cancer continues to grow across Aotearoa, experts say the goal should not simply be more testing, but better-informed testing that helps save lives.
When it comes to prostate cancer, knowledge, medical advice and early action remain the strongest tools available.
